Furthermore, prophylactic or therapeutic treatment with everolimus or rapamycin prevented HIV-1 acquisition (Fig. 4C) and controlled HIV-1 replication in ongoing viral infection of intestinal CD4+ T cells (Fig. 4E). This evidence concerns the gene CD4 and viral infectious disease.